Shanghai Haohai Biological Technology Co. Ltd

F:5HB Germany Biotechnology
Market Cap
$96.63 Million
€94.13 Million EUR
Market Cap Rank
#14198 Global
#1476 in Germany
Share Price
€2.62
Change (1 day)
+0.00%
52-Week Range
€2.58 - €3.26
All Time High
€4.70
About

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more

Shanghai Haohai Biological Technology Co. Ltd - Asset Resilience Ratio

Latest as of June 2025: 1.44%

Shanghai Haohai Biological Technology Co. Ltd (5HB) has an Asset Resilience Ratio of 1.44% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
€103.61 Million
Cash + Short-term Investments
Total Assets
€7.19 Billion
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Shanghai Haohai Biological Technology Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Haohai Biological Technology Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €103.61 Million 1.44%
Total Liquid Assets €103.61 Million 1.44%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Haohai Biological Technology Co. Ltd maintains only 1.44% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Haohai Biological Technology Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Haohai Biological Technology Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
ESSA Pharma Inc
NASDAQ:EPIX
Biotechnology 21.42%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for Shanghai Haohai Biological Technology Co. Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Shanghai Haohai Biological Technology Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.23% €87.85 Million €7.12 Billion +1.08pp
2023-12-31 0.16% €11.08 Million €7.11 Billion +0.06pp
2022-12-31 0.10% €6.75 Million €6.89 Billion +0.01pp
2021-12-31 0.09% €6.38 Million €6.95 Billion -0.15pp
2020-12-31 0.24% €15.14 Million €6.30 Billion -1.59pp
2018-12-31 1.83% €81.28 Million €4.44 Billion --
pp = percentage points